donepezil hydrochloride · Corium · NDA 212304
Adlarity
Earliest generic entry, as listed · earliest of 2 marketed strengths
11 Aug 2038
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 10966936.
Listed patents · 11 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10966936 | drug product, use U-3334 · sets the listed date | 11 Aug 2038 |
| US 10835499 | drug product, use U-3334 | 20 May 2038 |
| US 11648214 | drug product, use U-3334 | 23 Sep 2037 |
| US 10016372 | use U-3334 | 26 Jul 2037 |
| US 10300025 | drug product | 26 Jul 2037 |
| US 10307379 | drug product | 26 Jul 2037 |
| US 11103463 | use U-3334 | 26 Jul 2037 |
| US 9993466 | drug product | 26 Jul 2037 |
| US 11679086 | use U-3334 | 26 May 2037 |
| US 12161767 | drug substance, drug product, use U-3334 | 30 Dec 2036 |
| US 12168075 | use U-3334 | 30 Dec 2036 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 212304 · 001 · RLD · discontinued | system, transdermal | 5MG/DAY | 11 Aug 2038 |
| 212304 · 002 · RLD · discontinued | system, transdermal | 10MG/DAY | 11 Aug 2038 |